FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression-Reference-Cited by-同舟云学术

FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression

Published:2017-02 Issue: Volume:16 Page:51-62
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Heuer Timothy S.,Ventura Richard,Mordec Kasia,Lai Julie,Fridlib Marina,Buckley Douglas,Kemble George

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference50 articles.

1. Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation;Bollu;Oncotarget,2015

2. Posttranslational modification of tubulin by palmitoylation: I. In vivo and cell-free studies;Caron;Mol. Biol. Cell,1997

3. Vinblastine, a chemotherapeutic drug, inhibits palmitoylation of tubulin in human leukemic lymphocytes;Caron;Chemotherapy,2007

4. Single site alpha-tubulin mutation affects astral microtubules and nuclear positioning during anaphase in Saccharomyces cerevisiae: possible role for palmitoylation of alpha-tubulin;Caron;Mol. Biol. Cell,2001

5. Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal;Chuang;Biomed. Pharmacother.,2011

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of novel protein acylations in cancer;European Journal of Pharmacology;2024-09

2. S‐acylation of Ca²⁺ transport proteins in cancer;Chronic Diseases and Translational Medicine;2024-08-14

3. PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer;Biomedicine & Pharmacotherapy;2024-08

4. Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine‐ and cisplatin‐resistant models;Molecular Oncology;2024-06-14

5. Metabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy;Autoimmunity Reviews;2024-06